7 Update information
March 2024
After a partial review of this guidance, we updated the recommendation on nirmatrelvir plus ritonavir to include additional groups eligible for treatment (people with diabetes, obesity or heart failure, or aged 70 years or over).
We removed the recommendation on casirivimab plus imdevimab because the conditional marketing authorisation for casirivimab plus imdevimab for treating COVID‑19 was withdrawn.
June 2023
We added a section with supporting information on risk factors for progression to severe COVID‑19. This supporting information was provided by the independent advisory group commissioned by the Department of Health and Social Care.
April 2023
We updated the recommendations on nirmatrelvir plus ritonavir and sotrovimab to link to the updated independent advisory group report commissioned by the Department of Health and Social Care.
ISBN 978-1-4731-5810-8